Clinical Trials Logo

Cardiac Complications clinical trials

View clinical trials related to Cardiac Complications.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03211520 Completed - Clinical trials for Cardiac Complications

Magnetic Resonance Imaging:A Window to Anthracycline Toxicity

Start date: February 2013
Phase:
Study type: Observational

The study is being conducted to see which cardiac tests that monitor how the heart functions during and after treatment with anthracyclines are most effective. This study will assess a new way to check the heart function of children during and after cancer treatment. Currently, doctors use echocardiograms (heart ultrasound) to see how the heart is working. Echocardiograms are currently being done as part of standard of care prior to giving anthracycline chemotherapy doses and if any cardiac problems are suspected. The new method involves Cardiac Magnetic Resonance Imagining (CMRI) and a blood tests for certain biomarkers for heart health: High sensitivity troponin, Caspase, C-reactive Protein (CRP), ventricular derived B-type natriuretic peptide (BNP), Matrix Metalloproteinases (MMPs), Tissue inhibitors of metalloproteinases (TIMPs), C terminal propeptide of type I procollagen (PICP), C terminal telopeptide of collagen type I (CITP), Troponin I, and Bone Alkaline Phosphatase. The purpose of this study is to find out if CMRI and blood tests help us to find heart problems earlier, before they are detected by echocardiograms.

NCT ID: NCT03211442 Completed - Clinical trials for Breast Cancer Female

Implications of MEDIcal Low Dose RADiation Exposure - BReast Cancer Acute Coronary Events

MEDIRAD-BRACE
Start date: August 1, 2017
Phase:
Study type: Observational

MEDIRAD-BRACE aims to determine the relationship between 3D dose distributions in cardiac structures and the risk of acute coronary events (ACE) and other cardiac complications in breast cancer (BC) patients to develop and externally validate multivariable Normal Tissue Complication Probability (NTCP) models to assess the risk of ACE in individual patients based on cardiac dose metrics in the first 10 years after BC radiotherapy.

NCT ID: NCT02819739 Completed - Clinical trials for Cardiac Complications

Impact of Hyperoxia During Cardiopulmonary

CARDIOX
Start date: November 11, 2014
Phase: Phase 3
Study type: Interventional

The hypothesis implies that this work is the use of hyperoxia during cardiopulmonary bypass by his heart preconditioning effect is associated with a lower incidence of cardiac arrhythmias (atrial fibrillation, tachycardia or ventricular fibrillation) and lesions of myocardial ischemia-reperfusion injury in cardiac surgery postoperative.

NCT ID: NCT01916733 Completed - Glycemic Control Clinical Trials

A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study

Start date: January 2013
Phase: N/A
Study type: Observational

The aim of this study is to examine the effect of moderate glucose (blood sugar) control in diabetic and non-diabetic patients undergoing leg bypass surgery (LEB) or open abdominal aortic aneurysm (AAA) repair. We hypothesize that use of Fletcher Allen Health Care's current insulin infusion strategy will result in improved blood sugar control which will translate into decreased postoperative morbidity (fewer complications) and better long term outcomes when compared to patient outcomes at other institutions which utilize other blood sugar management strategies.

NCT ID: NCT00747331 Completed - Clinical trials for Cardiopulmonary Bypass

Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass

Start date: September 2008
Phase: Phase 4
Study type: Interventional

Cardiopulmonary bypass (CPB) for cardiac operations may be accompanied by different patterns of visceral underperfusion. This could result in clinical patterns of lactic acidosis but in the most severe cases there is the risk for mesenteric infarction (0.2% of the cases). Renal function as well may be impaired due to a low oxygen delivery, and acute renal failure occurs in 1-2% of cases. Fenoldopam mesilate is a selective splanchnic vasodilator when used at a dose < 0.1 mcg/kg/min. The experimental hypothesis of this randomized, controlled trial (RCT) is that the use of fenoldopam may determine a better visceral perfusion during CPB.